NCT05518201 2024-04-17
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
Shanghai Bovax Biotechnology Co., Ltd.
Beijing Health Guard Biotechnology, Inc